Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France

The Journal of Antimicrobial Chemotherapy
Valérie PotardFrench Hospital Database on HIV

Abstract

We assessed virological outcomes of darunavir use in France from 2012 to 2016, in three groups of people living with HIV (PLHIV): (i) antiretroviral (ARV)-naive PLHIV; (ii) ARV-experienced PLHIV switching to darunavir while failing therapy; and (iii) ARV-experienced PLHIV switching to darunavir while virologically controlled. Virological success (VS) was defined as a plasma HIV-1 viral load (VL) <50 copies/mL and virological failure (VF) as two consecutive VL >50 copies/mL or one VL >50 copies/mL followed by a treatment switch prior to the next VL measurement. The cumulative incidence of VS was assessed considering darunavir discontinuation, loss to follow-up and death as competing risks, while estimates of cumulative incidence of VF accounted for loss to follow-up and death. Among the 3235 ARV-naive PLHIV initiating darunavir, the 4 year cumulative incidence of VS was 80.9% and was associated with lower VL and higher CD4 cell counts. Among the 3485 ARV-experienced PLHIV switching to darunavir while failing therapy, the 4 year cumulative incidence of VS was 82.2% and was associated with lower VL. Among the 3005 ARV-experienced PLHIV switching to darunavir while virologically controlled, the 4 year cumulative incidence of VF was...Continue Reading

References

Oct 2, 2008·HIV Medicine·B G GazzardUNKNOWN BHIVA Treatment Guidelines Writing Group
Jan 19, 2012·International Journal of Epidemiology·Per Kragh AndersenHein Putter
Jun 15, 2012·AIDS·Marguerite GuiguetUNKNOWN FHDH-ANRS CO4
Feb 20, 2014·International Journal of Epidemiology·Murielle Mary-KrauseDominique Costagliola
Jul 20, 2014·JAMA : the Journal of the American Medical Association·Huldrych F GünthardPaul A Volberding
Oct 2, 2015·The Lancet. HIV·Nicholas I PatonUNKNOWN Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team
Oct 27, 2016·AIDS·Wolfgang StöhrUNKNOWN Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team
Apr 13, 2017·BMC Infectious Diseases·Tony AntoniouUNKNOWN Canadian Observational Cohort (CANOC) collaboration

❮ Previous
Next ❯

Citations

Aug 25, 2020·Current Pharmacology Reports·Linzi FanChunjuan Yang
Dec 2, 2020·The Journal of Antimicrobial Chemotherapy·Valérie PotardUNKNOWN French Hospital Database on HIV (FHDH-ANRS CO4)
May 29, 2021·Expert Opinion on Drug Safety·Camilla Ingrid HatlebergCaroline Sabin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.